Bibliography
- Murray CW, Verdonk ML, Rees DC. Experiences in fragment-based drug discovery. Trends Pharmacol Sci 2012;33:224-32
- Philpott M, Yang J, Tumber T, Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol BioSyst 2011;7:2899-908
- Arkin MR. Fragment-based discovery of modulators for PPI and allosteric enzymes. EFMC, Berlin; 2012. p. 45
- Baker M. Fragment-based lead discovery grows up. Nat Rev Drug Discov 2013;12:5-7
- de Graaf C. Fragments, fits, fingerprints: structure-based virtual screening for fragment-like GPCR ligands. EFMC, Berlin; 2012. p. 48
- Nair PC, Malde AK, Drinkwater N, Mark AE. Missing fragments: detecting cooperative binding in fragment-based drug design. ACS Med Chem Lett 2012;3:322-6
- Jordan JB, Poppe L, Xia X, Fragment based drug discovery: practical implementation based on 19F NMR spectroscopy. J Med Chem 2012;55:678-87
- Chen D, Errey JC, Heitman LH, Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A2A receptor with novel biological activity. ACS Chem Biol 2012;7:2064-73
- Hao GF, Wang F, Li H, Computational discovery of picomolar Q(o) site inhibitors of cytochrome bc1 complex. J Am Chem Soc 2012;134:11168-76
- Jhoti H. Fragment-based drug discovery – a decade of thinking small. EFMC, Berlin; 2012. p. 21
- Pihan E, Colliandre L, Guichou JF, Douguet D. e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. Bioinformatics 2012;28:1540-1
- Chidley C, Haruki H, Pedersen MG, A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. Nat Chem Biol 2011;7:375-83
- Micheli F, Andreotti D, Braggio S, Checchia A. A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template. Bioorg Med Chem Lett 2010;20:4566-8
- Larsen T, Link A. A timely reassessment of early prediction in the bioavailability of orally administered drugs. Angew Chem Int Ed Engl 2005;44:4432-4
- Dow GS, Milner EE, Wipf P, Mo T. Derivatives of mefloquine and associated methods for making and using. WO2010144434; 2010, 128pp
- Stump B, Eberle C, Schweizer WB, Pentafluorosulfanyl as a novel building block for enzyme inhibitors: trypanothione reductase inhibition and antiprotozoal activities of diarylamines. ChemBioChem 2009;10:79-83
- Wilcken R, Liu X, Zimmermann MO, Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. J Am Chem Soc 2012;134:6810-18
- Congreve M, Carr R, Murray C, Jhoti H. A ‘rule of three’ for fragment-based lead discovery? Drug Discov Today 2003;8:876-7
- Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20
- Alelyunas YW, Empfield JR, McCarthy D, Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorg Med Chem Lett 2010;20:7312-16
- Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44:235-49
- Ishikawa M, Hashimoto Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. J Med Chem 2011;54:1539-54
- Over B, Wetzel S, Grutter C, Natural-product-derived fragments for fragment-based ligand discovery. Nat Chem 2012;5:21-8
- Spinks D, Torrie LS, Thompson S, Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors. Chem Med Chem 2012;7:95-106
- Brand S, Cleghorn LA, McElroy SP, Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J Med Chem 2012;55:140-52
- Guan Y, Bissantz C, Bergstrom DE, Link A. 1,2,4-Trisubstituted cyclopentanes as platforms for diversity. Arch Pharm (Weinheim, Ger) 2012;345:677-86
- Mortenson PN, Murray CW. Assessing the lipophilicity of fragments and early hits. J Comput-Aided Mol Des 2011;25:663-7
- Rees D. LE, LLE and FBDD. EFMC, Berlin; 2012. p. 35
- Meiby E, Knapp S, Elkins JM, Ohlson S. Fragment screening of cyclin G-associated kinase by weak affinity chromatography. Anal Bioanal Chem 2012;404:2417-25
- Kamper C, Korpis K, Specker E, Sustainable synthesis and automated deposition: an accessible discovery screening library of fragment-like purines. Mol Divers 2012;16:541-51